Zheng Quan Ri Bao Wang·2025-09-17 12:41Core Insights - JD Health has launched the exclusive online debut of Bo You Ping (Dulaglutide Injection), a biosimilar for Trulicity, aimed at controlling blood sugar in adults with type 2 diabetes [1][2] - The product is the first and only approved biosimilar of Dulaglutide globally, addressing the growing diabetes prevalence in China, which exceeds 223 million patients [1][2] Company Developments - JD Health partnered with Shanghai Pharmaceuticals to promote Bo You Ping across all channels in mainland China, enhancing its market presence [2] - The collaboration aims to leverage JD Health's established online launch solutions and robust supply chain capabilities to facilitate patient access to innovative treatments [2] Industry Context - Type 2 diabetes is the most common form of diabetes, with traditional treatments facing challenges such as high medication frequency and risks of hypoglycemia [1] - GLP-1 receptor agonists, like Dulaglutide, are recommended for their significant blood sugar-lowering effects, weight loss benefits, and cardiovascular and renal protection [2]